These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35947641)

  • 1. Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function.
    Macha SJ; Koneru B; Burrow TA; Zhu C; Savitski D; Rahman RL; Ronaghan CA; Nance J; McCoy K; Eslinger C; Reynolds CP
    Cancer Res; 2022 Sep; 82(18):3345-3358. PubMed ID: 35947641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.
    Koneru B; Farooqi A; Nguyen TH; Chen WH; Hindle A; Eslinger C; Makena MR; Burrow TA; Wilson J; Smith A; Pilla Reddy V; Cadogan E; Durant ST; Reynolds CP
    Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34408079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative lengthening of telomeres does exist in various canine sarcomas.
    Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M
    Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
    Farooqi AS; Dagg RA; Choi LM; Shay JW; Reynolds CP; Lau LM
    J Neurooncol; 2014 Aug; 119(1):17-26. PubMed ID: 24792489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma.
    George SL; Parmar V; Lorenzi F; Marshall LV; Jamin Y; Poon E; Angelini P; Chesler L
    J Exp Clin Cancer Res; 2020 May; 39(1):78. PubMed ID: 32375866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of p53 and/or AKT as a new therapeutic approach specifically targeting ALT cancers.
    Ge Y; Wu S; Zhang Z; Li X; Li F; Yan S; Liu H; Huang J; Zhao Y
    Protein Cell; 2019 Nov; 10(11):808-824. PubMed ID: 31115790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative lengthening of telomeres in cancer stem cells in vivo.
    Bojovic B; Booth RE; Jin Y; Zhou X; Crowe DL
    Oncogene; 2015 Jan; 34(5):611-20. PubMed ID: 24531712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
    Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
    Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta.
    Novakovic B; Napier CE; Vryer R; Dimitriadis E; Manuelpillai U; Sharkey A; Craig JM; Reddel RR; Saffery R
    Mol Hum Reprod; 2016 Nov; 22(11):791-799. PubMed ID: 27604461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Loss of
    Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
    Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas.
    Ulaner GA; Hoffman AR; Otero J; Huang HY; Zhao Z; Mazumdar M; Gorlick R; Meyers P; Healey JH; Ladanyi M
    Genes Chromosomes Cancer; 2004 Oct; 41(2):155-62. PubMed ID: 15287028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALT: A Multi-Faceted Phenomenon.
    Sommer A; Royle NJ
    Genes (Basel); 2020 Jan; 11(2):. PubMed ID: 32012790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomeres and telomerase in sarcomas.
    Matsuo T; Shimose S; Kubo T; Fujimori J; Yasunaga Y; Ochi M
    Anticancer Res; 2009 Oct; 29(10):3833-6. PubMed ID: 19846916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
    Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
    J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: implications for telomere-based therapies.
    Gocha AR; Nuovo G; Iwenofu OH; Groden J
    Am J Pathol; 2013 Jan; 182(1):41-8. PubMed ID: 23260199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers.
    Henson JD; Reddel RR
    FEBS Lett; 2010 Sep; 584(17):3800-11. PubMed ID: 20542034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT-associated PML bodies.
    Jeyapalan JN; Mendez-Bermudez A; Zaffaroni N; Dubrova YE; Royle NJ
    Int J Cancer; 2008 Jun; 122(11):2414-21. PubMed ID: 18311780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.
    Flynn RL; Cox KE; Jeitany M; Wakimoto H; Bryll AR; Ganem NJ; Bersani F; Pineda JR; Suvà ML; Benes CH; Haber DA; Boussin FD; Zou L
    Science; 2015 Jan; 347(6219):273-7. PubMed ID: 25593184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.
    Heaphy CM; Subhawong AP; Hong SM; Goggins MG; Montgomery EA; Gabrielson E; Netto GJ; Epstein JI; Lotan TL; Westra WH; Shih IeM; Iacobuzio-Donahue CA; Maitra A; Li QK; Eberhart CG; Taube JM; Rakheja D; Kurman RJ; Wu TC; Roden RB; Argani P; De Marzo AM; Terracciano L; Torbenson M; Meeker AK
    Am J Pathol; 2011 Oct; 179(4):1608-15. PubMed ID: 21888887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells.
    Zhao S; Wang F; Liu L
    Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.